TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rapid HIV Testing and Counseling in Drug Abuse Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* HIV-negative or HIV status unknown~* No receipt of results from HIV test initiated within last 12 months~* Be able to communicate in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HIV rapid test & counseling (Type: EXPERIMENTAL): Participants will be offered an oral fluid HIV rapid test (via oral swab) and brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach (Project RESPECT-2 counseling). Prior to receiving testing, study participants must first provide consent for HIV testing. Consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test.
- HIV rapid test and info (Type: EXPERIMENTAL): Participants will be offered an oral fluid HIV rapid test (via oral swab). Prior to receiving testing, study participants must first provide consent for HIV testing. Again, consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test. Participants will receive rapid HIV testing and test results after signing the consent to be tested. In both Groups 1 and 2, participants who test reactive (preliminary positive) will be counseled on the sexual risk behaviors associated with transmission of HIV and the acquisition of STDs, as is current clinical practice with those testing HIV positive. Confirmed positives will be linked to HIV primary care.
- HIV testing referral (Type: ACTIVE_COMPARATOR): Participants randomized to group 3 will receive a referral list for HIV community-testing agencies. Each CTP site will have previously prepared an extensive referral list of testing sites in the surrounding geographic area. By virtue of their status as patients in the CTPs, they will receive whatever HIV testing and HIV education referrals the CTPs normally provide to their patients. This is the standard of care at CTPs that do not provide on-site testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is male with essential hypertension (high blood pressure)~* Participant is in good general health (with the exception of hypertension)~* Participant has a Body Mass Index (BMI) \<= 33 kg/m\^2 at the Screening visit~* Participant has a platelet count \>= 150,000 cu/mL at the Screening visit~* Participant has a positive AIx at the Screening visit~Exclusion Criteria:~* Participant has a history of stroke, chronic seizure, or major neurological disease~* Participant has a functional disability that can interfere with rising from a seated position to the standing position~* Participant has any history of a bleeding or clotting disorder~* Participant has a history of cancer~* Participant is unable to refrain from or anticipates the use of any prescription or non-prescription medication~* Participant consumes excessive amounts of alcohol or caffeinated beverages daily

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Panel A: MK-8266 BID, 1 mg/Placebo (Type: EXPERIMENTAL): MK-8266 1 mg (0.7 mg in the morning \[AM\] + 0.3 mg in the evening \[PM\]), or as matching placebo BID.
- Panel B: MK-8266 BID, 1.8 mg/Placebo (Type: EXPERIMENTAL): MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
- Panel C: MK-8266 TID, 1.8 mg/Placebo (Type: EXPERIMENTAL): MK-8266 TID, 1.8 mg (0.6 mg every 6 hours \[q6hr\]), or as matching placebo TID.
- Panel D: MK-8266 TID, 2.4 mg/Placebo (Type: EXPERIMENTAL): MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
- Panel E: MK-8266 TID, 2.4 mg/Placebo (Type: EXPERIMENTAL): MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All healthy, consenting, non-pregnant (as ascertained by history) residents at least 1 year of age of the study area~Exclusion Criteria:~* individuals who are too weak to get out of bed to receive the vaccine;~* pregnant women (identified through verbal screening); and~* those less than 1 year of age

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Cholera Vaccine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed malignancy or lymphoproliferative disease including the following:~  * Nasopharyngeal carcinoma~ * Hodgkin's lymphoma~ * African Burkitt's lymphoma~ * T-cell non-Hodgkin's lymphoma~ * B-cell non-Hodgkin's lymphoma if Epstein Barr Virus (EBV) positive~ * Other lymphomas associated with immunodeficiency or immunosuppression, including AIDS-related lymphoma~ * B-cell lymphoproliferative disorders~* Monoclonal or oligoclonal B-cell lymphoid disease (no polyclonal disease)~* EBV positive by immunohistochemistry or in situ hybridization~  * Negative serology for EBV allowed~PATIENT CHARACTERISTICS:~Age:~* 3 and over~Performance status:~* Any status~Hematopoietic:~* Absolute granulocyte count at least 1,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* Aminotransferase less than 2 times normal~Renal:~* Creatinine less than 3.0 mg/dL~* Creatinine clearance greater than 30 mL/min~Cardiovascular:~* No acute myocardial infarction within the past 6 months~* No atrial fibrillation within the past 6 months~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Prior bone marrow or stem cell transplantation allowed~* No concurrent immunotherapy~* No concurrent interferon or tacrolimus~Chemotherapy:~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered~* No concurrent cytotoxic chemotherapy~Endocrine therapy:~* No concurrent steroids~Radiotherapy:~* Recovered from prior radiotherapy~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 55 to 90 years of age, inclusive, at the time of informed consent.~* Subjects who are residing at their current location for at least 14 days before screening and are expected to remain at the same location for the duration of the trial.~* Subjects with diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA criteria.~* Subjects with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.~* Subjects with onset of symptoms of agitation at least 2 weeks prior to the screening visit.~* Subjects with a total score greater than or equal to 4 on the agitation aggression item of the NPI-NH or NPI/NPI-NH at the screening and baseline visits.~* Subjects who require pharmacotherapy for the treatment of agitation per the investigator's judgement, after an evaluation of reversible factors (eg, pain, infection, polypharmacy) and a trial of nonpharmacological interventions.~* Subjects must have a previous MRI or CT scan of the brain, which was performed after the onset of symptoms of dementia, with findings consistent with the diagnosis of Alzheimer's disease.~Exclusion Criteria:~* Subjects with dementia or other memory impairment not due to Alzheimer's disease.~* Subjects with history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism.~* Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.~* Subjects who have been diagnosed with an Axis I disorder (DSM-IV-TR criteria).~* Subjects with uncontrolled hypertension.~* Subjects with uncontrolled insulin-dependent diabetes mellitus (IDDM)~* Subjects with epilepsy or a history of seizures.~* Subjects considered in poor general health based on the investigator's judgment.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Once-Daily
- Brexpiprazole (flexible dose range 0.5 to 2 mg) (Type: EXPERIMENTAL): Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of acute myocardial infarction~* Vessel TIMI flow \< grade Ⅲ post-PCI~Exclusion Criteria:~* Heart failure of New York Heart Association (NYHA) class Ⅲ to class Ⅳ~* Sick sinus syndrome~* Atrioventricular block (grade Ⅱ and above)~* SBP ≤ 90mmHg or cardiogenic shock~* Heart Rate ≤60 bpm~* Pregnancy~* Renal or hepatic failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- D (Type: EXPERIMENTAL): If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
- V (Type: ACTIVE_COMPARATOR): If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
- N (Type: ACTIVE_COMPARATOR): If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: M-Tapa Block for Laparoscopic Inguinal Hernia Repair Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) classification I-II~* Scheduled for laparoscopic inguinal hernia repair surgery under general anesthesia~Exclusion Criteria:~* Bleeding diathesis~* Receiving anticoagulant treatment~* Known local anesthetics and opioid allergy~* Infection of the skin at the site of the needle puncture~* Pregnancy or lactation~* Patients who do not accept the procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group M = M-TAPA group (Type: ACTIVE_COMPARATOR): Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
- Group C = Control group (Type: NO_INTERVENTION): Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PATHOS Study Pain Assessment in Thoracic Oncologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lobectomy/ Segmentectomy plus lymphadenectomy (systematic or sampling) for cancer (not necessarily NSCLC) performed with a standardized, three portal minimally invasive approach.~Exclusion Criteria:~* Patients who are pregnant or lactating~* Morbid obesity (BMI \> 35 )~* Inability to understand and sign the Informed consent~* Proven allergy to local anesthetic drugs as required by this protocol~* Patients under chronic analgesics or neuroleptic therapy for any reason and/ or with baseline pain score (NRS scale) of 3 or more.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Serratus Plane Loco-regional block (Type: EXPERIMENTAL): * Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~* Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours~plus~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block
- Standard of Care (Type: NO_INTERVENTION): * Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~* Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Berberine Hyperglycemic Clamp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult healthy male, aged ≥18 and ≤45 years old.~2. Subject/ legal representative is able to understand and sign informed consent form.~3. Body mass index (BMI) 18-25 kg/m2.~4. Normal oral glucose tolerance test prior to study.~5. No family history of diabetes mellitus.~6. No medication treatment within 4 weeks prior to baseline visit and during the study.~7. Willing and able to comply with all study-related procedures, including not incorporating significant changes in diet.~Exclusion Criteria:~1. Infection with hepatitis (A, B, or C), HIV and syphilis.~2. History of allergic reaction to berberine or any component in the formulation of the study drugs.~3. Cumulative amount of blood loss (eg. blood donation) over 400mL within 3 months prior to baseline visit and during the study.~4. Alcohol drinking within 2 weeks prior to baseline visit and during the study.~5. Use of illegal drugs or positive in urine drugs screen.~6. Smoke during the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Berberine treatment (Type: EXPERIMENTAL): None
- Placebo control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases, between 18 and 80 years of age, who had undergone at least three lines of chemotherapy and had an expected survival time of at least 3 months.~Exclusion Criteria:~Patients fulfilling at least one of the following criteria will be excluded from participation in the study:~* Abnormal liver function classified as total bilirubin \>34 μmol/L or ALAT \> 3 times of the upper limit of normal (ULN). In case of metastases in the liver, the ALAT limit for exclusion is set to 5хULN.~* Abnormal kidney function defined by serum creatinine \>120 μmol/L.~* Abnormal coagulation capacity defined by the relative arbitrary concentration of coagulation factors 2,7,10; INR \>1.5.~* Verified metastases to the brain.~* Synchronous cancer except for non- melanoma skin cancer and early stage of cervical cancer.~* Abnormal hematology status defined by hemoglobin \< 9.0 g/dL, platelet count \< 100,000/mm\^3 or leucocytes \< 3 x 10\^9/L.~* Clinically significant abnormal ECG.~* Karnofsky performance status score \<60%.~* Pregnant or breast feeding women.~* Women of fertile age who do not want to be tested for possible pregnancy.~* Fertile female who do not want to use safe protection against pregnancy, starting one month before the start of the study treatment and lasting at least six weeks after.~* Uncontrolled bacterial, viral, fungal or parasite infection.~* Under systemic treatment with corticosteroids or other immunosuppressive drugs in the last 21 days before start of the trial treatment.~* Participating in another clinical trial with pharmaceuticals in the last six weeks before start of this trial treatment.~* Not able to understand information.~* Not willing or not able to give written consent to participate in the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BP-C1 (Type: EXPERIMENTAL): Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
- Placebo (Type: PLACEBO_COMPARATOR): Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 0-17;~* ASA Class I-II;~* Sign the informed consent form.~Exclusion Criteria:~* Patients with high risk of stomach satiety and reflux aspiration;~* Patients allergic to the study drug;~* Obesity or severe malnutrition;~* Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;~* Hypertension without treatment;~* Abnormal liver and kidney function (index ≥ 2 times the upper limit of normal reference range);~* Other congenital diseases or acute and chronic diseases that affect the observation of curative effect;~* Participate in other clinical studies within 4 weeks.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- P group (Type: ACTIVE_COMPARATOR): induction: Propofol 3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: propofol 5-10 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
- R group (Type: EXPERIMENTAL): induction: Remimazolam 0.3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: Remimazolam 1-3 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete